ライフサイエンスコーパス: how best to

1 Attention is increasingly focusing on how best to accelerate progress toward meeting the WHO's

2 rogressive disease, to answer issues such as how best to achieve and maintain optimum glycaemia witho

3 How best to achieve both weight loss and clinical benefi

4 ives, the aim is to facilitate discussion on how best to achieve consensus on this issue by driving t

5 ions about synapses, and discuss ideas about how best to achieve further progress in the field.

6 d to provide the most up to date guidance on how best to achieve multiple sclerosis stability during

7 How best to achieve this goal is unknown.

8 The question now is how best to achieve this?

9 A major challenge in tumor immunology is how best to activate the relatively low avidity self-spe

10 ose of this review is to update providers on how best to address asthma in adolescents.

11 ently, there is no comprehensive guidance on how best to address testing issues specific to MN partic

12 rious stages of their professions to discuss how best to address the toll racism takes on study desig

13 Awareness of these DDIs and how best to address them is of critical importance in op

14 DOAC DDIs, their underlying mechanisms, and how best to address them.

15 ore, we explore interactions that can inform how best to address these challenges.

16 However, there is minimal evidence on how best to address these factors and clinical inertia r

17 manufacturers, the FDA, and others determine how best to address this growing public health issue.

18 The MS research community needs to determine how best to address two key unanswered questions.

19 A key statistical issue is therefore how best to adjust for the two different probe designs.

20 We conclude with our recommendations for how best to advance our understanding of the relationshi

21 s methods enable informed decision making on how best to allocate limited resources that could lead t

22 osts also raises further questions regarding how best to allocate mental effort to minimize those cos

23 is is often suggested as a means of deciding how best to allocate resources, but some of its many eth

24 , there are no randomized studies evaluating how best to apply IO in early or advanced stages specifi

25 otic regimens, and (4) provides insight into how best to apply the COMPASS results into practice.

26 Understanding how best to apply these agents clinically and how they i

27 We are still learning how best to apply this new technology in an environment

28 variation, frustrating efforts to determine how best to apply this treatment tool.

29 n, childhood and adulthood; and to establish how best to apply this understanding to provide individu

30 ed ALL, now is an opportune time to consider how best to approach future therapy for AYA patients.

31 ing genome editing risks, it remains unclear how best to approach pre-clinical assessment of genome-e

32 ard understanding pathophysiology as well as how best to approach surgical management when indicated.

33 ient monitoring, when to change therapy, and how best to approach treatment options, including optima

34 How best to archive and mine the complex data derived fr

35 This review focuses on how best to ascertain the functional relevance of molecu

36 d highly interdisciplinary, understanding of how best to assemble these materials into films or hybri

37 with mortality, but there is no consensus on how best to assess abdominal adiposity.

38 researchers, there is increasing debate over how best to assess and ensure the fairness of algorithms

39 Future work should explore how best to assess the effect of communication coaching

40 How best to assess therapeutic misconception is unclear.

41 lectivity, allows medicinal chemists to plan how best to block its metabolism.

42 The problem of how best to bring this about is not easy to solve in hig

43 ate erupted in the London medical press over how best to calculate hospital mortality rates.

44 specialist, debate the guideline and discuss how best to care for a 71-year-old woman with metastatic

45 demiological studies have prompted debate on how best to characterise and diagnose this disorder.

46 However, the problem of how best to characterize ancestral relationships from th

47 the cell cycle is critical to understanding how best to clinically develop these agents, both as sin

48 ng randomized clinical trials are evaluating how best to combine currently available therapies, while

49 ver, there has been limited research done on how best to combine or fuse the two types of features.

50 rly diagnosis for glaucoma but it is unclear how best to combine the p.Gln368Ter status with polygeni

51 unit, there is a lack of understanding about how best to communicate the prognosis of a serious compl

52 We discuss, among other topics, how best to conceive of health privacy; the importance o

53 e and light pollution, whilst also examining how best to conserve urban biodiversity via features suc

54 gnment, little consensus has been reached on how best to construct profile-profile substitution score

55 There is significant controversy about how best to control cholera epidemics in refugee setting

56 tion of admixture mapping studies, including how best to control for multiple testing, particularly i

57 This literature is then used to recommend how best to convey preventive messages in today's cost-c

58 ed mixed results, exposing knowledge gaps in how best to define 'iron deficiency' and the handling of

59 and there remains ambiguity about how best to define additional pathways, such as the koni

60 There is disagreement on how best to define and investigate fear.

61 One major remaining question is how best to define disease progression.

62 is a lack of consensus among researchers on how best to define exceptional patients, and little has

63 ted with interstitial lung disease (ILD) are how best to define, diagnose, and treat connective tissu

64 presentative papers, however, struggled with how best to define, measure and validate recovery in its

65 burden of melanoma is necessary for deciding how best to deploy limited resources to achieve effectiv

66 with lymphoma, will be critical to determine how best to deploy MRD testing in routine practice and w

67 esearch, but researchers often struggle with how best to derive hits from HTS data.

68 magnetic molecules as a means of determining how best to describe the Nb-arene interactions.

69 A key challenge is that we still do not know how best to describe-and quantify-the many-to-many dynam

70 n these findings, we provide suggestions for how best to design and conduct energy balance experiment

71 amental research has been done to understand how best to design Lissajous pattern (LP)s for this use.

72 treatment and raise further questions about how best to design preclinical studies that can better p

73 Identifying how best to design protected areas is further complicate

74 roblems have emerged, including questions on how best to design these clinical trials and appropriate

75 However, our knowledge of how best to design these costly experiments and the effe

76 ife, clinicians are starting to grapple with how best to detect those at risk of postdeployment adjus

77 ion has opened a new therapeutic avenue, but how best to determine efficacy of remyelinating drugs re

78 Government agencies are presently analysing how best to develop an exit strategy from these measures

79 multicultural populations and on determining how best to develop such questionnaires.

80 develop consensus on when to screen for and how best to diagnose and treat NK.

81 n terms of aetiopathogenesis will help guide how best to direct therapy, based on these different und

82 However, it remains unclear how best to disentangle the impact of stress from the im

83 the TDP to enhance the treatment effect and how best to disseminate the TDP without compromising imp

84 How best to do this remains unknown.

85 th researchers and clinicians with regard to how best to document and address its unique health care

86 One topic that has come to the forefront is how best to effectively manage and interpret the large d

87 utionary pathways leading to bnAbs, and thus how best to elicit them, remains limited.

88 oach is proposed to promote discussion about how best to enable potential participants to make inform

89 education might help to shape behaviour, but how best to engage people with emergency communications

90 Evidence on how best to enhance discussions about CRC screening opti

91 recasts, an interdisciplinary perspective on how best to ensure ecologically viable continuity of glo

92 efits of the return of research results, and how best to ensure justice may differ from those of the

93 determining what interventions work but also how best to ensure they are provided to those who need t

94 these individuals and populations, including how best to ensure truly informed consent, how to minimi

95 and large dimensionality of sequence space, how best to estimate such probability distributions from

96 s at risk for developing a liver neoplasm or how best to evaluate a pediatric patient with a known li

97 of clinical trial endpoints have challenged how best to evaluate promising new therapeutics.

98 sorption from enabling ASD formulations, and how best to evaluate such formulations using in vitro ap

99 n and kinetics in vivo may lend insight into how best to evaluate the compound efficacy preclinically

100 f medical devices or generic patient models; how best to evaluate the credibility of PSMs has largely

101 preting correlation data and a discussion of how best to evaluate the effect of correlations on corti

102 ing session examined the practical issues of how best to evaluate the nutritionally at-risk host, esp

103 How best to evolve a desired trait?

104 ions to academia, industry and government on how best to expand the role of computation in their scie

105 ble were the critical questions raised as to how best to exploit aberrant signaling pathways associat

106 Furthermore, we discuss how best to exploit genetic background effects to broade

107 story in research publications; and consider how best to extend community-based curation and screenin

108 eter time series and raising the question of how best to extract insights from such rich data sets.

109 onent of skill acquisition involves learning how best to extract task-relevant information.

110 Questions remain about how best to focus surveillance efforts for COVID-19 and

111 has become commonplace, leading many to ask how best to follow these patients.

112 There is a clear need for consensus on how best to follow up patients with Fontan circulation a

113 In unresectable disease, the question is how best to get the patients to resection.

114 it has also reopened old controversies about how best to guide the development of this field.

115 open consent, and as controversy grows about how best to handle incidental genomic findings, these ap

116 is often critical for organisms to discover how best to harvest resources such as food and water.

117 inal causes but are essential to discovering how best to help the older aging autistic person.

118 re for the critical ill and injured learning how best to hook humans up to machines, we will spend th

119 enges for this emerging field: understanding how best to identify de novo genes, how they arise and w

120 presentative micrographs provide examples of how best to identify human HF stages, even in suboptimal

121 it from the procedure, no guidance exists on how best to identify such patients.

122 nce of learning, and provide no consensus as how best to identify when learning has occurred.

123 We also provide technical advice about how best to image Brainbow-expressing tissue.

124 n basic research, but questions remain about how best to implement and monitor compliance.

125 nciples are formulated to assist in deciding how best to implement each.

126 The challenge is how best to implement imaging in clinical practice to ma

127 e embraced and efforts are made to determine how best to implement in practice.

128 ngs of this approach, provide guidance about how best to implement it, and describe lessons learned f

129 ence on eligibility for same-day initiation, how best to implement it, and its impact on outcomes rem

130 to conventional decongestion practices, and how best to implement novel therapies.

131 spital admission: a greater understanding of how best to implement them in a wide range of contexts a

132 have relatively little guidance on when and how best to implement these methods in their investigati

133 Our understanding on how best to implement this cell-replacement strategy for

134 Future studies are needed to determine how best to implement this evolving armamentarium of tre

135 multaneously, many countries are considering how best to improve the management of their blood invent

136 ppropriately designed studies to investigate how best to improve this situation.

137 and memory; we have little understanding of how best to incorporate physical activity during the day

138 , additional studies are needed to determine how best to incorporate psyllium into existing preventio

139 clinicians and scientists must now determine how best to incorporate rapid changes in our biologic un

140 d on performing clinical trials to determine how best to incorporate rapid detection of MDRO carriage

141 women in whom the tests should be used, and how best to incorporate test results into decision makin

142 However, how best to incorporate these advances into frontline th

143 , there remains a lack of clear guidance for how best to incorporate these assertions about race and

144 hydrophobicity, molecular size) and evaluate how best to incorporate this finding into full-scale des

145 idual tumors will be critical in determining how best to incorporate this promising agent into the ar

146 of genetic exchange, a daunting challenge is how best to infer the correct relationships between spec

147 ers, plans, and physicians as they determine how best to inform patients about managed care.

148 ntional microbiological methods, and discern how best to integrate mNGS into current testing algorith

149 ams, in which training directors must decide how best to integrate neuroscience teaching in a rapidly

150 and to develop consensus recommendations on how best to integrate PSMA PET into ongoing and upcoming

151 It remains unclear how best to integrate recent discoveries regarding gliom

152 matized clinical problem and lack of data on how best to integrate scalable risk models into clinical

153 xisting medicines, research is needed now on how best to integrate the treatment of neglected tropica

154 sensations originating from the same object, how best to integrate them.

155 More research is needed to evaluate how best to integrate these approaches into pain treatme

156 increasing use of TRT raises the question of how best to integrate TRT into multimodality protocols.

157 mechanism of cell wall assembly and suggest how best to interfere with the process for future antibi

158 ience and psychology, can provide handles on how best to interpret and exploit genetic mapping result

159 od for a specific application or for gauging how best to interpret different sources of data.

160 e care for patients with heart failure (HF), how best to interpret longitudinally collected patient-r

161 lity of 24-hour esophageal pH monitoring and how best to interpret pH test results, 2) definitively d

162 from mother to child presents the dilemma of how best to interpret the benefits and risks of breastfe

163 e of DNA microarrays, questions remain about how best to interpret the wealth of gene-by-gene transcr

164 f septic cardiomyopathy, with an emphasis on how best to interpret this condition in the clinical con

165 g high-dimensional and heterogeneous data is how best to interrogate increasingly specific subphenoty

166 ile there is as yet no clear consensus about how best to intervene therapeutically in CJD, prion infe

167 We consider how best to leverage genomic data and recent experimenta

168 However, little guidance exists for how best to leverage implementation science to promote c

169 rtheless, a remaining unanswered question is how best to leverage the new data to parameterize models

170 s critical information about tumor response; how best to leverage this for predicting recurrence-free

171 alike, the current challenge is to determine how best to make SDM a reality in everyday clinical prac

172 How best to make use of that information is an active ar

173 e prospective studies are needed to evaluate how best to manage all manifestations of skin inflammati

174 Research is needed to understand how best to manage author FCOIs during guideline creatio

175 ies affect the benefit of device therapy and how best to manage device advisories.

176 There remains controversy about how best to manage intracranial pressure on the ICU; we

177 brain, what is the clinical presentation and how best to manage it.

178 s a need to study why they are so common and how best to manage them.

179 tribute to successful biological control and how best to manipulate augmentative releases into greenh

180 logy, are vast, but the crucial questions of how best to match the most appropriate sensors and senso

181 shortly, the UK and EU should be considering how best to maximize the potential of the numerous brill

182 e discrete impact of specific strategies and how best to measure outcomes to inform efforts to increa

183 There is debate about how best to measure patient-reported outcomes (PROs) in

184 aining this goal will require a consensus on how best to measure the numbers of persistently infected

185 Current research is focused on evaluating how best to measure the patient assessments and incorpor

186 objective of health care, yet it is unclear how best to measure this in the ICU setting.

187 parents, there is very limited knowledge on how best to meet the mental health needs of young people

188 rvey to better understand what they were and how best to meet them, in the primary care environment.

189 However, how best to minimise the time spent taking cytotoxic dru

190 tients make optimal informed decisions about how best to minimize the risk of this serious complicati

191 responsible for the behavioral sequelae and how best to model the effects of early adversity.

192 ay in autoimmunity will provide insight into how best to modulate this interaction to achieve therape

193 allograft, yet there remains no consensus on how best to monitor drug therapy.

194 raft and could, therefore, determine help on how best to monitor patients with dnDSA.

195 ts to help might make the problem worse, and how best to move forwards.

196 purpose and value of theoretical models and how best to navigate collaborations between experimental

197 Policymakers are assessing how best to navigate through the ongoing epidemic, with

198 pecifically, research is needed to determine how best to operationalize disclosure processes so as to

199 prevent future inequities in development and how best to operationalize them.

200 ions on these parameters, as well as explore how best to optimise recovery and quality of life for su

201 arch and policy work is needed to understand how best to optimize sepsis survivorship across the urba

202 Controversy exists about how best to organize systems of care for patients with o

203 ssion data, relatively little is known as to how best to perform feature selection or classification

204 about which new diagnostics to scale up and how best to position them in diagnostic algorithms.

205 the matrix interact with the algorithm, and how best to predict the probability of observing a previ

206 However, there is a misunderstanding about how best to prepare cumulative antimicrobial susceptibil

207 ugment CTL function, raising the question of how best to present tumor-associated MHC class I epitope

208 Research is needed to better understand how best to prevent and treat hepatitis C in substance u

209 One research challenge is to determine how best to prevent cardiac arrest during severe hemorrh

210 drug development and in the determination of how best to prevent hepatotoxicity after drug approval.

211 for Disease Control and Prevention (CDC) on how best to prevent infections.

212 little is known about their risk factors and how best to prevent them.

213 or death (SCA/SCD) keep alive a debate as to how best to prevent these tragedies.

214 s on what disease models are appropriate and how best to proceed once high-density genome maps become

215 How best to project data across single-cell atlases is a

216 The question of how best to protect the human population against a poten

217 ed specific knowledge about transmission and how best to protect themselves.

218 dge generation, dissemination, and uptake on how best to provide care, not just determining what inte

219 c arrest, there is little direct guidance on how best to provide interfacility transport.

220 mbers of procedures to attain competence and how best to provide procedural training.

221 We further propose that studies focused on how best to provide T cell help to B cells that produce

222 d with expertise in building knowledge about how best to provide this care.

223 ces between psychological processes, and for how best to pursue a unified science of the mind.

224 es in models can affect parameter mapping or how best to quantify similarities between model output a

225 These include how best to rapidly and efficiently identify key genes r

226 However, uncertainty persists as to how best to regress ECG LVH.

227 s commentary examines the evidence regarding how best to replete phosphorous in the hypophosphatemic

228 gy, an artist and a cell biologist - explore how best to represent the entire process of cell divisio

229 ing biological terrorism lies in focusing on how best to respond to a terrorist attack.

230 address these issues, and may not understand how best to respond to their patients' spiritual needs.

231 Empirical studies are required on how best to scale up antiviral treatment and combine tre

232 nor-derived infections raise the question of how best to screen donors without excessive restriction

233 However, it is not clear how best to screen for frailty in preoperative surgical

234 It is uncertain how best to screen pregnant women for the presence of fe

235 n improves performance but have not explored how best to select features.

236 are important for cancer cells, determining how best to select patients, and developing technologies

237 cer (CRPC) introduce new treatment dilemmas: how best to sequence these options to maximally benefit

238 However, many empiric questions about how best to structure and implement disclosure processes

239 data, but also because of uncertainty about how best to study consciousness in the absence of the ca

240 Conflicting findings led to questions of how best to study the role of this variant in human auto

241 omen's experiences, the evidence base around how best to support female employees experiencing the me

242 Further research is needed to understand how best to support service members and veterans who may

243 It is important to consider how best to sustain population protection in the long te

244 ntervention coverage in these groups, and on how best to sustain, focus, and intensify efforts to pro

245 ceived a simple, 3-step instruction sheet on how best to take photographs using a smartphone (interve

246 econdary analysis to receive instructions on how best to take photographs with smartphones.

247 hich sources are the most harmful, let alone how best to target policies to mitigate them.

248 programs in plant health, it remains unclear how best to target surveillance resources to achieve thi

249 ed within the plasma membrane will determine how best to target this family of receptors therapeutica

250 inking, and then focus on recent research on how best to teach science to children from preschool to

251 tors have long wrestled with the question of how best to teach their clients be they humans, non-huma

252 One challenging question is how best to test for significant methylation differences

253 e model's emphasis on temporality challenges how best to think of static art forms.

254 surgeons need to spend focused attention on how best to train and educate upcoming surgical trainees

255 tant question and hence goal in catalysis is how best to transfer the synthetic and mechanistic insig

256 Research should focus not only on how best to transition long-acting products to these pop

257 e preferences of their patients to determine how best to translate research to the bedside.

258 It is unclear how best to translate these population-level results to

259 How best to translate this increase in immune responsive

260 ities for AF, there is no clear consensus on how best to treat AF with concomitant HFrEF.

261 Other questions include how best to treat an acute attack as well as the optimal

262 Making decisions on how best to treat cancer patients requires the integrati

263 How best to treat HIV-infected children who require tube

264 g informal 'risk assessments' in relation to how best to treat individual patients.

265 Inadequate evidence exists to determine how best to treat infants with gastroschisis.

266 S, and describe our current understanding on how best to treat MOG-Ab-associated disease.

267 More data are needed to determine how best to treat patients with stage II and stage III M

268 er are elderly, information remains scant on how best to treat these patients.

269 However, there is no consensus on how best to treat these patients.

270 es the promise it still holds, and considers how best to turn promise into reality.

271 t have led me to change my long-term view on how best to understand mind/brain interactions.

272 that it may be in decline, and it considers how best to understand the future spread, containment, a

273 lar basis of mental disorders, to rethinking how best to undertake research on the aetiology, assessm

274 Future research is needed on how best to use available drug treatments in real world

275 ortunities will begin to provide guidance on how best to use diet and nutrition to manage cancer in p

276 be useful to step for planners to determine how best to use existing platforms for delivering new in

277 ating its mode of action will help to refine how best to use fenofibrate in the management of diabeti

278 essential to improving our understanding of how best to use forecasts to improve public health respo

279 t also of practical significance in learning how best to use MLEs in the germline transformation of i

280 How best to use newer molecular tests for RTI in combina

281 titative framework can guide policymakers on how best to use nonpharmaceutical interventions and prio

282 It is time to rethink how best to use repeat events data in heart failure tria

283 However, little evidence exists on how best to use SIAs to strengthen RI.

284 ysicians to interpret the results and decide how best to use the information.

285 ve better epidemiologic data, we cannot know how best to use the system's scarce mental health resour

286 d by a medical technology in decisions about how best to use the technology.

287 any new tests, including an understanding of how best to use them to inform optimal antibiotic prescr

288 culture techniques and we are still learning how best to use these approaches.

289 , high-dimensional models; and it is unclear how best to use these models for prediction.

290 ealth care professionals, who must determine how best to use these technologies to optimize patient c

291 ns, were identified, along with questions of how best to use this body of information to reduce human

292 Future research is needed to determine how best to use this technique for risk stratification.

293 Priority research questions include how best to use tools to identify the required staffing

294 over a 1 year period in order to understand how best to utilise milk for processing throughout the y

295 vation energies used for EThcD to understand how best to utilize acquisition time.

296 However, many questions remain regarding how best to utilize BBMs at the population level.

297 which glutamine acts will lead to insight on how best to utilize glutamine as a nutritional therapy.

298 its effects will lead to an understanding of how best to utilize glutamine as both a pharmacologic an

299 Lastly, we detail how best to utilize these SV annotations in the analysis

300 identified, and further debate is needed on how best to validate chronic disease diagnoses in the GP